We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Sel3.5

Selegiline Research

Mostly mechanism / observational

172 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Selegiline studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 1978–2026 with a typical study size of 903 participants.

Based on 172 studies · 9 meta-analyses · 153 RCTs · 4,723 total participants

Confidence

High confidence

By outcome

Neuroprotection & cognition
Mostly mechanism / observational76 studies
Lifespan & aging (animal, mixed)Extends lifespan/function in some animal models (mixed); a healthspan-oriented repurposing target, not a proven human longevity intervention. · Not established
Mostly mechanism / observational45 studies
Safety profile
Mostly mechanism / observational9 studies

Slowing down

Only 7 studies in the last 5 years · Latest meta-analysis: 2025

197820022026

1Meta-Analysis1998

Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H · Neurology (1998)

Selegiline Research

Mostly mechanism / observational

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials.

Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.

Selegiline for Alzheimer's disease.

Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.

Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.

The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.

Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study.

A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.

Selegiline as initial treatment in de novo parkinsonian patients.

An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.

Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.

Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study.

[Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].

Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial.

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.

Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.